Atenção farmacêutica em pacientes idosos portadores de dislipidemias como fator de prevenção em eventos ateroscleróticos e aterotrombóticos: um estudo piloto

• Ano de defesa: 2014
• Autor(a) principal: Lima, Mariana Moreira de [UNESP]
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Estadual Paulista (Unesp)
• Palavras-chave em Português: Sistema cardiovascular - Doenças; Atenção farmacêutica; Hiperlipidemia; Aterosclerose; Níveis séricos; Colesterol; Hyperlipidemia
• Link de acesso: http://hdl.handle.net/11449/145473; http://www.athena.biblioteca.unesp.br/exlibris/bd/cathedra/13-10-2016/000868038.pdf

Dyslipidemia is a disorder that predispose to atherosclerosis and atherothrombosis. Elderly are predisposed to dyslipidemia and these appear due to comorbidities. It has been reported that pharmaceutical care can contribute to the control of dyslipidemia and other risk factors for atherosclerosis. The objective of this study was to do pharmaceutical care in elderly patients with dyslipidemia to promote control of cholesterol (total and fractions) and to reduce other risk factors to decrease atherosclerotic events. This is a pilot study, experimental type, randomized, of 187 elderly with aged over 60 years, who were living in two Institutions for elderlies in the city of Araraquara SP, in the period between September 2013 to February 2014. The model of pharmaceutical care was used Pharmacist's workup of Drugs Therapy at the University of Minnesota. The sample was randomized into a control group that received usual medical care and intervention group, which in addition to the medical care received pharmacotherapy follow-up. In order to evaluate the effectiveness of pharmacotherapy follow-up, clinical parameters were collected (blood glucose, glycated hemoglobin, blood pressure, heart rate, waist circumference, total cholesterol, LDL, HDL, triglycerides, Body Mass Index(BMI) and Framingham Risk). Of the 187 participants, 119 were diagnosed with dyslipidemia, and low HDL association with other type of dyslipidemia was in the most prevalent . The 119 patients were randomized, 60 in the intervention group and 59 in the control group. In the group that received the intervention, 108 drug related problems were found, and the problem of security as found because many prescriptions drugs potentially inappropriate for the elderly. 179 pharmaceutical interventions were conducted, about education-related health interventions on non-pharmacological treatment of dyslipidemia ...